Loading clinical trials...
Loading clinical trials...
Checkpoint inhibitor such as anti-CTLA-4 and anti-PD-1 are known to block inhibitory signals and increase the immune antimutoral response. Nivolumab and Ipilimumab association is considered as a more ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Nice
NCT05655312 · Recurrent Melanoma (Skin), Metastatic Melanoma, and more
NCT06956690 · Melanoma (Skin), Non Small Cell Lung Cancer, and more
NCT00003641 · Melanoma (Skin)
NCT03543969 · Melanoma (Skin), Skin Cancer, and more
NCT04079166 · Malignant Melanoma, Melanoma (Skin), and more
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-maritimes
CHU de Montpellier
Montpellier, Occitanie
CHRU de Lille
Lille
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions